Roche

Actemra: first IL-6 receptor inhibitor for RA; BuTrans: first once-weekly transdermal opioid; Onsolis: opioid buccal film for breakthrough cancer pain; Victoza: first GLP-1 analogue for type 2 diabetes

Improving productivity and patient care in long-term care facilities

Hoffmann-La Roche will soon be introducing Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor inhibitor to be approved for the treatment of rheumatoid arthritis (RA).

IWK Health Centre partners with NRC

A look at drugs in the late stages of development in Canada